Skip to content

Effect of Tegileridine Fumarate on Postoperative Recovery Quality in Patients Undergoing Laparoscopic Sleeve Gastrectomy:A randomized controlled double-blind clinical trial

Effect of Tegileridine Fumarate on Postoperative Recovery Quality in Patients Undergoing Laparoscopic Sleeve Gastrectomy:A randomized controlled double-blind clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108386
Enrollment
Unknown
Registered
2025-08-29
Start date
2025-09-28
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative recovery in patients undergoing Laparoscopic Sleeve Gastrectomy

Interventions

Tegileridine Fumarate group (T group):Administration of Tegileridine Fumarate for anesthesia induction and postoperative analgesia
Sufentanil group (S group):Administration of Sufentanil for anesthesia induction and postoperative analgesia

Sponsors

The First People's Hospital of Lianyungang
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with a BMI >=40 kg/m^2, a BMI of 35-40 kg/m^2 with associated complications, or a BMI of 30-35 kg/m^2with poorly controlled type 2 diabetes and/or hypertension; 2.Aged between 18 and 65 years; 3.ASA physical status classification of I-III; 4.Clear understanding and voluntary participation in this study, with signed informed consent; 5.All patients received training on VAS scoring and the use of patient-controlled analgesia pumps.

Exclusion criteria

Exclusion criteria: 1. Allergy to experimental drugs; 2. Patients with acute or severe bronchial asthma; 3. Known or suspected gastrointestinal obstruction, including patients with paralytic intestinal obstruction; 4. Patients who have been taking non-steroidal anti-inflammatory drugs, opioids, and sedatives for a long time; 5. Any neurological or psychiatric illness, including history or treatment of substance abuse, anxiety, or depression; 6. Patients with vital organ dysfunction, cardiac dysfunction (unstable ischemic heart disease, severe pulmonary hypertension, etc.), liver dysfunction (palnine aminotransferase or aspartate aminotransferase value>=2 times the upper limit of normal or total bilirubin >1.5 times the upper limit of normal), renal dysfunction (serum creatinine >=2mg/dl.

Design outcomes

Primary

MeasureTime frame
QoR-15 score;

Secondary

MeasureTime frame
time to first rescue analgesia;cumulative opioid consumption in PCIA;CRP;postoperative antiemetic usage rate;IL-6;amount of rescue analgesia required postoperatively;patient satisfaction with analgesia;number of PCIA attempts;Adverse reactions within 72 hours after surgery;Kroenke Score;VAS of pain scores (at rest/ during turning over);

Countries

China

Contacts

Public ContactYong Wu

The First People's Hospital of Lianyungang

18961325621@163.com+86 18961325621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026